Health insurance enrollment and availability of medications for substance use disorders

Psychiatric Services

Volumn 68, Issue 1, 2017, Pages 41-47

  Abraham, Amanda J ^a   Rieckmann, Traci ^c   Andrews, Christina M ^d   Jayawardhana, Jayani ^b  

^a Department of Public Administration and Policy ^*  (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; BUPRENORPHINE; DISULFIRAM; METHADONE; NALTREXONE; CENTRAL NERVOUS SYSTEM AGENTS;

ALCOHOLISM; CONFERENCE PAPER; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; HEALTH CARE AVAILABILITY; HEALTH INSURANCE; HUMAN; IDAHO; MAJOR CLINICAL STUDY; MEDICAID; PREVALENCE; SOUTH DAKOTA; UNITED STATES; VERMONT; HEALTH CARE DELIVERY; STATISTICS AND NUMERICAL DATA;

CENTRAL NERVOUS SYSTEM AGENTS; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH; MEDICAID; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 85008184054     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201500470     Document Type: Conference Paper

References (59)

1. National Survey on Drug Use and Health. Bethesda, Md, Substance Abuse and Mental Health Services Administration, 2012
2. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. Morbidity and Mortality Weekly Report 60: 1489-1492, 2011
3. CDC Grand Rounds: prescription drug overdoses-a US epidemic. Morbidity and Mortality Weekly Report 61:10-13, 2012
4. Degenhardt L, Bucello C, Mathers B, et al: Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 106:32-51, 2011
5. Mokdad AH, Marks JS, Stroup DF, et al: Actual causes of death in the United States, 2000. JAMA 291:1238-1245, 2004
6. The BHSIS Report: Substance Abuse Treatment Before the Affordable Care Act: Trends in Social and Economic Characteristics of Facilities and Admissions, 2006 to 2011. Rockville, Md, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, 2014
7. Amass L, Ling W, Freese TE, et al: Bringing buprenorphinenaloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. American Journal on Addictions 13(suppl 1):S42-S66, 2004
8. Amato L, Minozzi S, Davoli M, et al: Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews 10:CD004147, 2011
9. Amato L, Minozzi S, Davoli M, et al: Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews 9: CD005031, 2011
10. Garbutt JC, Kranzler HR, O'Malley SS, et al: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293:1617-1625, 2005
11. Krupitsky E, Nunes EV, Ling W, et al: Injectable extended-release naltrexone for opioid dependence. Lancet 378:665-666, 2011
12. O'Malley SS, Garbutt JC, Gastfriend DR, et al: Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. Journal of Clinical Psychopharmacology 27:507-512, 2007
13. Rösner S, Hackl-Herrwerth A, Lehert LS, et al: Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews 9: CD004332, 2011
14. Rösner S, Hackl-Herrwerth A, Leucht S, et al: Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews 12:CD001867, 2010
15. Comer SD, Sullivan MA, Yu E, et al: Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Archives of General Psychiatry 63: 210-218, 2006
16. Donaher PA, Welsh C: Managing opioid addiction with buprenorphine. American Family Physician 73:1573-1578, 2006
17. Fiellin DA, Pantalon MV, Chawarski MC, et al: Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. New England Journal of Medicine 355:365-374, 2006
18. Kahan M, Srivastava A, Ordean A, et al: Buprenorphine: new treatment of opioid addiction in primary care. Canadian Family Physician Medecin de Famille Canadien 57:281-289, 2011
19. Ziedonis DM, Amass L, Steinberg M, et al: Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphinenaloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug and Alcohol Dependence 99: 28-36, 2009
20. Baser O, Chalk M, Fiellin DA, et al: Cost and utilization outcomes of opioid-dependence treatments. American Journal of Managed Care 17(suppl 8):S235-S248, 2011
21. Baser O, Chalk M, Rawson R, et al: Alcohol dependence treatments: comprehensive health care costs, utilization outcomes, and pharmacotherapy persistence. American Journal of Managed Care 17(suppl 8):S222-S234, 2011
22. Bryson WC, McConnell J, Korthuis PT, et al: Extended-release naltrexone for alcohol dependence: persistence and health care costs and utilization. American Journal of Managed Care 17(suppl 8): S222-S234, 2011
23. Incorporating Alcohol Pharmacotherapies Into Medical Practice. TIP 49. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2009
24. Helping Patients Who Drink Too Much: A Clinician's Guide. NIH pub no 07-3769. Bethesda, Md, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 2007
25. Principles of Drug Addiction Treatment: A Research-Based Guide. NIH pub no 09-4180. Bethesda, Md, National Institutes of Health, National Institute on Drug Abuse, 2009
26. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Chevy Chase, Md, American Society of Addiction Medicine, 2015
27. Abraham AJ, Knudsen HK, Rieckmann T, et al: Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. Journal of Studies on Alcohol and Drugs 74:258-265, 2013
28. Ducharme LJ, Knudsen HK, Roman PM: Trends in the adoption of medications for alcohol dependence. Journal of Clinical Psychopharmacology 26(suppl 1):S13-S19, 2006
29. Mark TL, Kassed CA, Vandivort-Warren R, et al: Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug and Alcohol Dependence 99:345-349, 2009
30. Pecoraro A, Ma M, Woody GE: The science and practice of medication-assisted treatments for opioid dependence. Substance Use and Misuse 47:1026-1040, 2012
31. Abraham AJ, Knudsen HK, Roman PM: A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation. Journal of Studies on Alcohol and Drugs 72: 669-677, 2011
32. Abraham AJ, Rieckmann T, McNulty T, et al: Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addictive Behaviors 36:576-583, 2011
33. Garner BR: Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review. Journal of Substance Abuse Treatment 36:376-399, 2009
34. Heinrich CJ, Hill CJ: Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Services Research 43:951-970, 2008
35. Heinrich CJ, Cummings GR: Adoption and diffusion of evidencebased addiction medications in substance abuse treatment. Health Services Research 49:127-152, 2014
36. Knudsen HK, Ducharme LJ, Roman PM: Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. Journal of Substance Abuse Treatment 30:363-373, 2006
37. Abraham AJ, Roman PM: Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. Journal of Studies on Alcohol and Drugs 71:460-466, 2010
38. Fuller BE, Rieckmann T, McCarty D, et al: Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment 28:273-280, 2005
39. Knudsen HK, Roman PM, Oser CB: Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine 4:99-107, 2010
40. Abraham AJ, Knudsen HK, Rothrauff TC, et al: The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation. Journal of Substance Abuse Treatment 38:275-283, 2010
41. Knudsen HK, Abraham AJ, Johnson JA, et al: Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. Journal of Substance Abuse Treatment 37:307-312, 2009
42. Roman PM, Johnson JA: Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment 22:211-218, 2002
43. Andrews CM, D'Aunno TA, Pollack HA, et al: Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Medical Care Research and Review 71:43-60, 2014
44. Chandra A, Skinner J: Technology growth and expenditure growth in health care. Journal of Economic Literature 50:645-680, 2012
45. Finkelstein A: The aggregate effects of health insurance: evidence from the introduction of Medicare. Quarterly Journal of Economics 122:1-37, 2007
46. Gaynor M, Town RJ: Competition in Health Care Markets. NBER Working Paper 17208. Cambridge, Mass, National Bureau of Economic Research, 2011
47. Weisbrod BA: The health-care quadrilemma-an essay on technologicalchange, insurance, quality of care, and cost containment. Journal of Economic Literature 29:523-552, 1991
48. Patient Protection and Affordable Care Act of 2010. Public Law no 111-148, 124 Stat 119, 42 USC x18001, 2010
49. Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008, HR 6983, 110th Cong
50. Carman KG, Eibner C, Paddock SM: Trends in health insurance enrollment, 2013-15. Health Affairs 34:1044-1048, 2015
51. State summaries FY 2011/2012; in SAMHSA Grant Awards by State. Rockville, Md, Substance Abuse and Mental Health Services Administration. http://media.samhsa.gov/statesummaries/index.aspx. Accessed June 1, 2015
52. National Survey of Substance Abuse Treatment Services. Bethesda, Md, Substance Abuse and Mental Health Services Administration, 2012
53. American Community Survey. Washington, DC, US Census Bureau, 2012
54. Area Health Resource File. Rockville, Md, Health Resources and Services Administration, 2012
55. Stata, Release 13, Statistical Software. College Station, Tex, StataCorp LP, 2013
56. Ducharme LJ, Abraham AJ: State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy 3:17, 2008
57. Stewart MT, Horgan CH: Health services and financing of treatment. Alcohol Research and Health 33:389-394, 2011
58. Vestal C: Many people with substance abuse problems may find few to treat them. Kaiser Health News, April 8, 2015
59. Rieckmann T, Abraham A, Zwick J, et al: A longitudinal study of state strategies and policies to accelerate evidence-based practices in the context of systems transformation. Health Services Research 50:1125-1145, 2015